Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Exelixis, Inc.    EXEL

EXELIXIS, INC.

(EXEL)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/18/2020 11/19/2020 11/20/2020 11/23/2020 11/24/2020 Date
19.255(c) 19(c) 18.91(c) 18.39(c) 18.41 Last
3 534 476 2 262 321 2 987 883 3 094 988 1 420 700 Volume
-0.08% -1.32% -0.47% -2.75% +0.11% Change
More quotes
Financials (USD)
Sales 2020 931 M - -
Net income 2020 59,1 M - -
Net cash position 2020 1 302 M - -
P/E ratio 2020 108x
Yield 2020 -
Sales 2021 1 159 M - -
Net income 2021 148 M - -
Net cash position 2021 1 529 M - -
P/E ratio 2021 39,7x
Yield 2021 -
Capitalization 5 705 M 5 705 M -
EV / Sales 2020 4,73x
EV / Sales 2021 3,60x
Nbr of Employees 617
Free-Float 98,1%
More Financials
Company
Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ... 
More about the company
Notations Surperformance© of Exelixis, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about EXELIXIS, INC.
08:46aEXELIXIS : to Webcast Fireside Chats as Part of Virtual Investor Conferences in ..
AQ
11/23EXELIXIS : to Webcast Fireside Chats as Part of Virtual Investor Conferences in ..
BU
11/05EXELIXIS : 3Q Earnings Snapshot
AQ
11/05EXELIXIS, INC. : Results of Operations and Financial Condition, Financial Statem..
AQ
11/05EXELIXIS : Announces Third Quarter 2020 Financial Results and Provides Corporate..
BU
11/02EXELIXIS : to Webcast Fireside Chats as Part of Virtual Investor Conferences in ..
BU
10/28Ono and Takeda Submit Supplemental Application for Opdivo and CABOMETYX Combi..
AQ
10/28Exelixis Announces Takeda and Ono Submit Supplemental Application for CABOMET..
AQ
10/27EXELIXIS : Announces First Patient Enrolled in Phase 1 Trial Cohort Evaluating X..
AQ
10/27EXELIXIS : Announces Takeda and Ono Submit Supplemental Application for CABOMETY..
BU
10/26EXELIXIS : Announces First Patient Enrolled in Phase 1 Trial Cohort Evaluating X..
BU
10/23EXELIXIS : to Release Third Quarter 2020 Financial Results on Thursday, November..
AQ
10/22EXELIXIS : to Release Third Quarter 2020 Financial Results on Thursday, November..
BU
10/20BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Accepts for Priority Re..
AQ
10/19BRISTOL MYERS SQUIBB : Exelixis Get Priority Review for Kidney-Cancer Treatment
DJ
More news
News in other languages on EXELIXIS, INC.
07/02Floride, vaccin et Fed au menu
07/02EN DIRECT DES MARCHES : Airbus, Ipsen, Alstom, Flatex, Tesla, Soitec, Biophyt..
07/02IPSEN : collaboration clinique pour le cabozantinib
07/02Ipsen s'allie à Exelixis et Roche pour développer son médicament Cabometyx
02/21EXELIXIS, INC. : Veröffentlichung des Jahresergebnisses
More news
Chart EXELIXIS, INC.
Duration : Period :
Exelixis, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXELIXIS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 30,85 $
Last Close Price 18,39 $
Spread / Highest target 118%
Spread / Average Target 67,7%
Spread / Lowest Target 35,9%
EPS Revisions
Managers
NameTitle
Michael M. Morrissey President, Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Christopher J. Senner Chief Financial & Accounting Officer, Executive VP
Gisela M. Schwab Chief Medical Officer & President-Medical Affairs
Peter Lamb Chief Scientific Officer & EVP-Scientific Strategy
Sector and Competitors
1st jan.Capitalization (M$)
EXELIXIS, INC.4.37%5 705
GILEAD SCIENCES, INC.-7.83%75 074
VERTEX PHARMACEUTICALS-0.49%56 654
REGENERON PHARMACEUTICALS39.45%55 264
WUXI APPTEC CO., LTD.63.37%39 757
BIONTECH SE214.34%25 644